Henry Meds vs ShedRx (2026): prices, structure, verdict

On tirzepatide, ShedRx↗ is cheaper: $289 versus $349 a month all-in — a $60 monthly gap, $720 across a year of maintenance dosing.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, Henry Meds↗ is cheaper: $179 versus $249 a month all-in — a $70 monthly gap, $840 across a year of maintenance dosing, and Henry Meds's figure is dose-flat while ShedRx's structure is not.

§ Side by side

§ Each record, read aloud

The two records, condensed

Henry Meds: the record, condensed

On tirzepatide, the number that matters at Henry Meds is $349 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #10 of 17 verified programs, with the floor $134/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $100 a month. A year at this figure: $4,188 monthly-billed.

Start with the load-bearing figure: $179 a month, all-in, is what Henry Meds charges for semaglutide at the 2.4 mg basis. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $179 is the whole subscription, which makes Henry Meds unusually easy to compare and unusually easy to leave.

Context for that figure: it ranks #9 of 20 in the verified semaglutide index — $46/month above the floor (Oak Longevity, $133) — and sits $170 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $2,148.

Operationally at Henry Meds: shipping included; commitment none month-to-month; cancellation check terms before prepaying; pharmacy not publicly named — ask in writing before paying; states: most states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Henry Meds page · visit Henry Meds ↗

ShedRx: the record, condensed

On tirzepatide, the number that matters at ShedRx is $289 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. Pricing steps with the dose here: from $199 at entry to $289 at the 10 mg basis. Multiply the wrong one of those by twelve and your budget is off by $1,080 a year, which is why every ranking on this site uses the larger number.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $289 is the whole subscription, which makes ShedRx unusually easy to compare and unusually easy to leave.

To place the number: #5 of 17 verified programs, with the floor $74/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $160 a month. A year at this figure: $3,468 monthly-billed.

Start with the load-bearing figure: $249 a month, all-in, is what ShedRx charges for semaglutide at the 2.4 mg basis. Pricing steps with the dose here: from $175 at entry to $249 at the 2.4 mg basis. Multiply the wrong one of those by twelve and your budget is off by $888 a year, which is why every ranking on this site uses the larger number.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $249 is the whole subscription, which makes ShedRx unusually easy to compare and unusually easy to leave.

Context for that figure: it ranks #13 of 20 in the verified semaglutide index — $116/month above the floor (Oak Longevity, $133) — and sits $100 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $2,988.

Operationally at ShedRx: shipping included; commitment none month-to-month; cancellation 72-hour notice before the next billing cycle; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the ShedRx page · visit ShedRx ↗

Tirzepatide: the duel in full

Put the two tirzepatide figures side by side and hold them there: ShedRx at $289, Henry Meds at $349 — a $60 monthly spread that compounds to $720 over a maintenance year and $1,440 over two.

Structure sharpens the gap: Henry Meds’s figure is dose-flat (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill the same), while ShedRx’s is not — so Henry Meds’s number is a ceiling and ShedRx’s advertised entry ($199) is a floor. Comparing a ceiling to a floor flatters the floor; this site compares maintenance to maintenance, which is the table above.

Semaglutide: the duel in full

The semaglutide arithmetic between these two is short: $179 (Henry Meds) against $249 (ShedRx). $70 a month sounds survivable; $840 a year is a decision.

Structure sharpens the gap: Henry Meds’s figure is dose-flat (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill the same), while ShedRx’s is not — so Henry Meds’s number is a ceiling and ShedRx’s advertised entry ($175) is a floor. Comparing a ceiling to a floor flatters the floor; this site compares maintenance to maintenance, which is the table above.

A way to feel the $60 monthly gap: over a year it funds 2.5 extra months at ShedRx’s own rate — the difference is not decoration, it is medication. Over two years it compounds to $1,440, which is the horizon at which structural details (prepaid ladders, membership drag, dose-tier repricing) start mattering more than the sticker itself.

Run the same two programs on the committed basis: Henry Meds $349/mo month-to-month against ShedRx $289/mo month-to-month. The order holds: ShedRx leads on both readings, so plan structure sharpens the verdict here rather than reversing it. Whichever basis fits your commitment level, the upfront totals above are the honest units.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: Henry Meds $1,047 monthly; ShedRx $867 monthly — best path favors ShedRx by $180. 6 months: Henry Meds $2,094 monthly; ShedRx $1,734 monthly — best path favors ShedRx by $360. 12 months: Henry Meds $4,188 monthly; ShedRx $3,468 monthly — best path favors ShedRx by $720. 24 months: Henry Meds $8,376 monthly; ShedRx $6,936 monthly — best path favors ShedRx by $1,440.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

The same clock, on semaglutide

3 mo: Henry Meds $537 vs ShedRx $747 — $210 to Henry Meds. 6 mo: Henry Meds $1,074 vs ShedRx $1,494 — $420 to Henry Meds. 12 mo: Henry Meds $2,148 vs ShedRx $2,988 — $840 to Henry Meds. 24 mo: Henry Meds $4,296 vs ShedRx $5,976 — $1,680 to Henry Meds.

Same rules as above: prepaid figures are upfront commitments, and the 24-month lines extend the 12-month rate as a stated assumption. Where the two molecules crown different winners between these two programs, that split is itself the finding — molecule choice and provider choice are separate decisions.

§ Structure vs structure

Everything besides the price

Coverage: Henry Meds publishes “most states”; ShedRx publishes “not published” — for anything short of an explicit 50-state claim, intake is the final word.

Neither names its pharmacy publicly — the single most useful disclosure in this category, missing on both sides; ask each, in writing, before paying either.

Exit terms: Henry Meds — none month-to-month; check terms before prepaying. ShedRx — none month-to-month; 72-hour notice before the next billing cycle.

Evidence: Henry Meds third-party reported (captured 2026-08-05); ShedRx source-verified (2026-08-05).

The pattern worth internalizing: in this market, structural honesty and price honesty travel together. Programs that publish pharmacies and state lists tend to publish real maintenance prices; programs that hide one usually hide the other.

In the full tirzepatide index these two sit at #10 and #5 of 17: between them lie 4 other programs, and the whole ladder is at cheapest tirzepatide providers. In the full semaglutide index these two sit at #9 and #13 of 20: between them lie 3 other programs, and the whole ladder is at cheapest semaglutide providers.

§ If you move

Switching between Henry Meds and ShedRx

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (Henry Meds: check terms before prepaying; ShedRx: 72-hour notice before the next billing cycle) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings